Previously, we developed an immunoliposome conjugated with anti-EGFR antibody, which successfully targeted glioma cells for delivery of BSH and bioluminescence imaging in vitro and in vivo [39,43]. This evidence concerns the gene EGFR and central nervous system cancer.